)
Edge28 Aug 2026
Bigger, Sharper, IMAX: A Blockbuster Business
How IMAX turned an unscalable, large-screen format into the center of blockbuster filmmaking through cameras, projection, and remastering technology.
SynAct Pharma
SynAct Pharma (SYNACT) investor relations material
SynAct Pharma Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary20 Aug, 2026
Executive summary
Report covers Q2 and first half of 2026, focusing on R&D in inflammatory diseases, especially resomelagon for RA and viral infections.
ADVANCE Phase 2b study topline data reported, supporting Phase 3 planning and business development.
Positive momentum in partnering discussions and strategic financing secured to support ongoing and future studies.
Financial highlights
Net sales were SEK 0 for both Q2 and H1 2026; company remains pre-revenue.
Q2 operating expenses decreased 19% year-over-year to SEK 24,556 thousand.
Q2 loss after tax was SEK 22,032 thousand, improved from SEK 27,522 thousand last year.
Cash and cash equivalents at June 30, 2026, were SEK 14,228 thousand, down from SEK 68,890 thousand.
Equity/assets ratio at 82% as of June 30, 2026.
Outlook and guidance
Focus on advancing resomelagon to Phase 3 in RA and expanding into viral infection indications.
Preparation for regulatory submissions to FDA and EMA in 2H 2026.
Ongoing business development to secure commercial partnerships and additional funding.
Cash runway expected to last into Q3 2027 following new financing facility.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from SynAct Pharma
- Resomelagon shows strong efficacy and safety in RA, targeting a large, unmet market with broad potential.SYNACT
Company presentation - Resomelagon shows strong clinical promise in RA and viral infections, backed by robust IP and leadership.SYNACTCompany presentation
- Advancing resomelagon for RA and viral infections, targeting major unmet needs with strong IP.SYNACTCompany presentation
- RA, PMR, and dengue programs advance with strong funding and patent protection, targeting major deals.SYNACTCMD 2025
- 40 mg resomelagon showed strong efficacy and safety in early RA, supporting phase III plans.SYNACTStudy result
- Awaiting key phase II-B data for a novel immune therapy, with broad expansion and partnerships planned.SYNACTAktiedagarna 2026
- ADVANCE Phase 2b RA study completed dosing; cash runway extended after SEK 51.9M share issue.SYNACTQ1 2026
- Upcoming clinical data and strong financials position the pipeline for major partnering deals.SYNACTCMD 2026
- R&D-driven losses deepened in 2025, but major clinical milestones set up a transformative 2026.SYNACTQ4 2025
Next SynAct Pharma earnings date
Q3 20263 Nov, 2026
SynAct Pharma
Next SynAct Pharma earnings date
Q3 20263 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage